The FINANCIAL — Daiichi Sankyo Company, Limited on August 24 announced that it has obtained approval in Japan for a supplementary indication of “tachycardiac atrial fibrillation” for Artist Tablets 2.5mg, 10mg and 20mg for the treatment of hypertension, angina, and chronic heart failure.
Artist features alpha-blocking action alongside nonselective beta-blocking with vasodilation action, and based on the beta-blocking effect, a lowering of the heart rate is shown. In both Japanese and international guidelines, heart rate control therapy is recommended for atrial fibrillation patients, according to Daiichi Sankyo.
As a result of requests received from atrial fibrillation-related medical societies, Daiichi Sankyo conducted Phase 3 clinical trials in Japan and obtained supplementary approval for Artist Tablets for the aforementioned indication.
Daiichi Sankyo aims to contribute further in the field of medicine by providing a new option through this drug to patients and medical professionals involved in the treatment of atrial fibrillation, as well as by continuing to expand its product lineup.